Form 8-K

8-K — ACCENDRA HEALTH INC/VA/

Accession: 0001104659-26-108405

Filed: 2026-09-17

Period: 2026-09-16

CIK: 0000075252

SIC: 5047 (WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ach-20260916x8k.htm (Primary)

EX-10.1 (ach-20260916xex10d1.htm)

EX-99.1 (ach-20260916xex99d1.htm)

GRAPHIC (ach-20260916xex10d1g001.jpg)

GRAPHIC (ach-20260916xex10d1g002.jpg)

GRAPHIC (ach-20260916xex10d1g003.jpg)

GRAPHIC (ach-20260916xex10d1g004.jpg)

GRAPHIC (ach-20260916xex10d1g005.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ach-20260916x8k.htm · Sequence: 1

Accendra Health, Inc._September 16, 2026

0000075252false00000752522026-09-162026-09-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 16, 2026

Accendra Health, Inc.

(Exact name of registrant as specified in its charter)

Virginia

001-09810

54-1701843

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation or organization)

File Number)

Identification No.)

4435 Waterfront Drive, Suite 300,

Glen Allen, Virginia

23060

(Address of principal executive

offices)

(Zip Code)

Registrant’s telephone number, including area code (804) 277-4304

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $2 par value per share

ACH

New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 17, 2026, Accendra Health, Inc. (the “Company” or “Accendra Health”) announced that it named Kenneth Gardner-Smith as the Company’s next President and Chief Executive Officer. Mr. Gardner-Smith, who has served on the Company’s Board of Directors since March 2022, is expected to assume the role early in the fourth quarter 2026. He will succeed Edward A. Pesicka, who previously announced his intent to retire in August. Mr. Pesicka will remain in the role of President and CEO until Mr. Gardner-Smith assumes the role, at which point Mr. Pesicka will also retire from the Board of Directors, as previously announced. Mr. Pesicka will continue to serve as an advisor to Mr. Gardner-Smith and the Company’s leadership team to ensure a smooth transition. Mr. Gardner-Smith will continue to serve on the Accendra Health Board of Directors and the Board’s Executive Committee as a non-independent director and will step down from his roles on the Our People & Culture and Audit Committees of the Board. These roles will be filled by an independent Board member.

Biographical information regarding Mr. Gardner-Smith is set forth in the Company’s definitive proxy statement for its 2026 annual meeting of stockholders filed with the Securities and Exchange Commission on April 2, 2026 and such information is incorporated by reference herein. Except for the arrangements described in this Current Report on Form 8-K, Mr. Gardner-Smith is not a party to any transaction, and there is no currently proposed transaction with Mr. Gardner-Smith, that is required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are no family relationships between Mr. Gardner-Smith and any of the Company’s directors or executive officers. Mr. Gardner-Smith is not a party to any arrangement or understanding regarding his selection as an officer.

On September 16, 2026, the Company entered into an offer letter with Mr. Gardner-Smith describing the terms of his employment with Accendra Health (the “Offer Letter”). Pursuant to the Offer Letter, Mr. Gardner-Smith will be entitled to: (i) an annual base salary of $1,000,000 and will be eligible for a target annual cash bonus under the Company’s 2026 Annual Incentive Plan equal to 130% of his base salary, prorated to reflect the period he is employed during the fiscal 2026 year; (ii) participation in the Company’s annual long-term incentive program, with a target grant date fair value for Mr. Gardner-Smith’s annual equity award of $6,000,000, with the 2026 awards to be granted 25% in restricted stock units of the Company, 25% in stock-settled performance share units of the Company (“PSUs”) and 50% in cash-settled PSUs; (iii) a one-time sign-on cash bonus of $650,000, which shall be payable following six months of employment with the Company, subject to repayment in the event Mr. Gardner-Smith voluntarily resigns without Good Reason (as defined in the Executive Change in Control Severance Agreement) within 24 months of his employment commencement date; (iv) a one-time inducement grant of cash-settled stock appreciation rights with a target value of $2,000,000, which have a ten-year term and vest in equal annual installments over three years, first becoming exercisable upon the three-year anniversary of the grant date; and (v) participation in the Company’s group benefit programs. Mr. Gardner-Smith will be covered by the Company’s Officer Severance Policy dated February 27, 2025 (filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025) and will enter into an Executive Change in Control Severance Agreement in substantially the form filed as Exhibit 10.42 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

The foregoing description of the Offer Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Offer Letter, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On September 17, 2026, the Company issued a press release announcing the planned appointment of Mr. Gardner-Smith as President and Chief Executive Officer and Scott Lloyd to role of Chief Commercial Officer of the Company. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01.

Other Matters.

Accendra Health also today named Scott Lloyd to the role of Chief Commercial Officer, effective October 5, 2026. Mr. Lloyd most recently served as Chief Development and Strategy Officer at Evergreen Nephrology. Prior to that, Mr. Lloyd co-founded and built Extrakare LLC, a durable medical equipment company. The Company created the position to bring commercial strategy, sales, and provider and payor partnerships under a single leader, simplifying the commercial structure, instilling greater discipline and accountability, and driving renewed focus on growth as Accendra Health scales as a pure-play home-based care company. Mr. Lloyd will report to the Chief Executive Officer and serve on the executive leadership team.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

10.1

Offer Letter, accepted September 16, 2026, between the Company and Kenneth Gardner-Smith.

99.1

Press Release of the Company, dated September 17, 2026 (furnished pursuant to Item 7.01).

104

Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACCENDRA HEALTH, INC.

September 17, 2026

/s/ Heath H. Galloway

Heath H. Galloway

Executive Vice President, General Counsel and Corporate Secretary

EX-10.1

Filename: ach-20260916xex10d1.htm · Sequence: 2

Exhibit 10.1

September 7, 2026

Mr. Kenneth Gardner-Smith

5195 SW 75th Street

Miami, FL 33143

Dear Kenny:

This letter confirms our conversations regarding you joining Accendra Health (the “Company”)

as President and Chief Executive Officer. This letter establishes and details the terms of your

offer of employment. This letter is not an employment contract and should not be construed as

such, but it is intended to provide a detailed understanding of your compensation, benefits, and

the terms and conditions of your employment. All amounts paid to you in connection with your

employment, in whatever form, will be subject to withholding for taxes and other deductions as

required by law. This offer letter shall be governed by the laws of the Commonwealth of

Virginia, without regard to conflict of laws principles.

Compensation:

Start Date: October 1, 2026, or as mutually agreed. This offer will expire if

not accepted by September 18, 2026.

Position Title: President and Chief Executive Officer. You will also remain a

member of the Board of Directors of the Company (the “Board”)

following your election to such position. You will not render

commercial or professional services to any other person or

organization while employed by the Company, whether or not

for compensation, without prior Board approval. You may

continue your current professional and non-profit board roles,

but any additional board service requires Board approval.

Base Salary: Your starting annualized base salary will be $1,000,000, paid bi-weekly. Your base salary will be reviewed at least annually for

possible adjustments by the Our People & Culture Committee.

Docusign Envelope ID: 844B85AC-AE8D-8C2E-8109-45A86F4870A1

Annual Incentive: You will be eligible to participate in the Company’s Annual

Incentive Program (“AIP”) with a target opportunity of 130% of

base salary. Terms and conditions for the 2026 AIP shall be those

approved for other members of the Company Leadership Team

(“CLT”). Your 2026 AIP opportunity will be prorated to reflect the

period you are employed during the 2026 fiscal year. To earn an

AIP payment, you must remain continuously employed through

the payment date.

Annual LTI: You will be eligible to participate in the Company’s annual equity

award program with a target grant date value of $6,000,000. All

LTI awards are subject to Board approval and are governed by

the applicable plan documents and award agreements. Your

2026 LTI award at target will be granted on the following terms:

• Mix: 25% RSUs, 25% stock-settled PSUs, and 50% cash-settled PSUs

• PSU performance measured 100% on relative TSR, and

otherwise based on the same terms and conditions as

other CLT members for 2026

• Target value converted to RSUs or PSUs using a share

price of $5.29

• Maximum PSU payout: 300% of target

• Maximum cash-settled PSU payout: 4x target value

Cash Sign-On Bonus: You will be eligible to receive a cash sign-on bonus in the gross

amount of $650,000, payable following six months of

employment with the Company. If you voluntarily resign from

your employment without Good Reason within the first 24

months of your employment, you agree to repay to the Company

the full amount of the cash sign-on bonus. For purposes of this

offer letter, Good Reason shall have the meaning set forth in the

Executive Change in Control Severance Agreement.

Docusign Envelope ID: 844B85AC-AE8D-8C2E-8109-45A86F4870A1

Inducement Grant: You will be eligible to receive an inducement grant with a target

value of $2,000,000 on the following terms:

• Instrument: Cash-settled SARs

• Target value converted to SARs using grant date stock

price, adjusted for Black-Scholes valuation

• Ten-year term; vesting 1/3 annually; exercisable after

three years

• Maximum payout: 20x target value ($40M)

Group Benefits:

You will be eligible for all current Company group benefit programs (e.g., health, dental, life

insurance, disability, 401(k), etc.) as described below, subject to the terms and conditions of the

applicable plan or program document as in effect from time to time. The Company reserves the

right to modify, amend, suspend or terminate any plan at any time without prior notice.

401(k) Plan: Following 30 days of employment, you will be eligible to defer

into the Company’s 401(k) plan (subject to IRS limitations). After

one year of service, you will be eligible to receive a Company

match of 100% on the first 3% of base salary.

Health Dental & Vision

Insurance:

You will be eligible to participate in the Company's health,

dental, and vision insurance programs beginning on your initial

date of hire with 31 days to enroll.

Flexible Benefit Program: You may set aside pre-tax dollars for health care and dependent

care expenses through tax-advantaged accounts, subject to IRS

rules.

Vacation: Following 90 days of employment, you will participate in the

Company’s Flexible PTO Program, which allows you to take time

off as needed while still meeting your work obligations.

Docusign Envelope ID: 844B85AC-AE8D-8C2E-8109-45A86F4870A1

Life Insurance: Upon employment, you will be eligible for basic life coverage of

$10,000 and you may elect supplemental coverage for yourself, a

spouse, and/or dependents.

Disability: You may participate in the Company’s teammate-paid short-term

and long-term disability programs.

Executive Benefits:

As an executive officer, you will be eligible for additional fringe benefits as summarized below.

All benefits are governed by the applicable plan documents and may be amended or

terminated in accordance with their terms.

Change in Control: You will be offered an Executive Change in Control Severance

Agreement providing benefits upon a qualifying termination

following a “change in control” of the Company.

Officer Severance: You will be eligible for severance upon a qualifying termination

under the Company’s Officer Severance Policy.

Tax, Financial Planning: You will be eligible for a $15,000 annual allowance for tax and

financial planning services from a firm of your choice (excluding

the Company’s independent auditor).

Executive Physical: You will be eligible for a Company-paid annual executive physical

and membership in a medical concierge service.

Conditions of Employment:

This offer is contingent upon the satisfactory completion of your background check, reference

check, employment verification, and all other applicable checks. You will also be required to

complete new hire forms and related documentation, in accordance with Company policy, and

you will be required to produce documents establishing your identity and authorization for

employment in the United States on your first day of work. Additionally, please note that your

employment with the Company is on an at-will basis, meaning that either you or the Company

Docusign Envelope ID: 844B85AC-AE8D-8C2E-8109-45A86F4870A1

can terminate the employment relationship at any time and for any lawful reason or no reason.

You hereby authorize the Company to conduct background checks on you from time to time,

subject to applicable law.

By signing below, you represent that you have never been debarred, suspended, or otherwise

declared ineligible to participate in any federal healthcare or other programs. You further

represent that accepting this offer and commencing employment will not violate, conflict with,

or breach (i) any agreement to which you are a party, including any employment agreement or

any non-competition, non-solicitation, confidentiality, or other restrictive covenant with any

current or former employer or third party, or (ii) any policy or rule applicable to you from any

current or former employer. You represent that you will not provide the Company with or use

or disclose in the course of your employment, any confidential, proprietary, or legally protected

information belonging to any current or former employer or third party. If you have questions

about the ownership of any documents or information, you should discuss them with your

current or former employer(s) before removing or copying such materials. You also

acknowledge that you have reviewed the terms and conditions contained herein and there are

no other terms, agreements, or promises, verbal or written, outside of this offer letter. Finally,

you agree to follow the Company’s policies, procedures, and directives in effect during your

employment.

We are delighted at the prospect of you joining our team and look forward to welcoming you to

Accendra Health. Please do not hesitate to reach out to me if you have any questions or if you

would like to discuss further.

Sincerely,

Mark Beck

Chair of the Board of Directors

Accendra Health, Inc.

Acceptance of Offer as Presented:

Date:

Kenneth Gardner-Smith

Docusign Envelope ID: 844B85AC-AE8D-8C2E-8109-45A86F4870A1

9/16/2026

EX-99.1

Filename: ach-20260916xex99d1.htm · Sequence: 3

Exhibit 99.1

Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth

Gardner-Smith to Succeed Ed Pesicka Following Previously Announced Retirement

Company Announces Scott Lloyd as Chief Commercial Officer

Richmond, VA – September 17, 2026 – Accendra Health, Inc. (NYSE: ACH) (the “Company”) today named Kenneth Gardner-Smith as the Company’s next President and Chief Executive Officer. Gardner-Smith, who has served on the Company’s Board of Directors since March 2022, is expected to assume the role early in the fourth quarter 2026. He will succeed Edward A. Pesicka, who announced his intent to retire in August.

Gardner-Smith brings deep experience running large-scale patient care operations and guiding transformations. He currently serves as Chief Executive Officer of Veritas Veterinary Partners, a national specialty and emergency veterinary platform, where he spearheaded a strategy reset and executive rebuild that delivered double-digit average quarterly revenue growth and significant margin expansion throughout his tenure since 2024. Prior to that, Gardner-Smith served in a variety of operating roles over 13 years at DaVita, including nine years as a senior P&L owner managing $1.5 billion in operations and most recently as a senior executive, where he supported teams across more than 3,000 facilities in 13 countries.

Gardner-Smith has been part of the Board’s long-term executive succession planning for several years, having been identified as a potential successor soon after joining the Board. He was selected following a comprehensive search process that considered both internal and external candidates. The Board is confident that Gardner-Smith is the optimal leader to guide Accendra Health into its next chapter. He brings a combination of attributes uniquely well-suited to this moment: the operating experience of an outside healthcare executive, paired with the firsthand knowledge of the Company’s strategy, culture, and people. Gardner-Smith was also involved in the Board’s annual strategic planning process and will leverage his strong track record to execute on key initiatives that accelerate growth in higher-margin categories, enhance operating efficiency, and drive continued investment in the business.

“We are thrilled to welcome Kenny as Accendra Health’s next President and Chief Executive Officer,” said Mark Beck, Chair of Accendra Health's Board of Directors. “Kenny brings more than 15 years of operating leadership in reimbursement-driven healthcare and deep knowledge of our strategy and operations, making him the Board’s unanimous choice to lead Accendra Health. I look forward to partnering closely with him and the leadership team to build on the steps the Company has taken in the past year and deliver on the significant opportunities ahead.”

Beck continued, “On behalf of the Board, I want to thank Ed Pesicka for his more than seven years of leadership. Thanks to his efforts, Kenny inherits a strong foundation with enhanced financial flexibility to pursue greater efficiency and growth.”

“I’m proud to lead Accendra Health as we enter this next chapter,” said Kenneth Gardner-Smith, incoming President and Chief Executive Officer. “Having served on the Board since 2022, I’ve had a front-row seat to Accendra Health’s transformation into a pure-play home-based care company. My priority now is to build on our progress and invest in the business to drive long-term growth and stability, all while keeping patients, providers, and partners at the center of everything we do. I’m confident we have the right strategy to get there, and I'm looking forward to building on Ed's legacy alongside the team.”

Pesicka will remain in his role of President and CEO until Gardner-Smith assumes the role, at which point he will also retire from the Board of Directors, as previously announced. He will continue to serve as an advisor to Gardner-Smith and the leadership team to ensure a smooth transition. Importantly, the Company expects no disruption to its operations or its ability to serve patients, providers, and partners throughout the transition.

Gardner-Smith will continue to serve on the Accendra Health Board of Directors and the Board’s Executive Committee as a non-independent director and will step down from his roles on the Our People & Culture and Audit Committees.

Chief Commercial Officer

Accendra Health also today named Scott Lloyd to the role of Chief Commercial Officer, effective October 5, 2026. The Company created the position to bring commercial strategy, sales, and provider and payor partnerships under a single leader, simplifying the commercial structure, instilling greater discipline and accountability, and driving renewed focus on growth as Accendra Health scales as a pure-play home-based care company. Lloyd will report to the Chief Executive Officer and serve on the executive leadership team.

Lloyd brings more than two decades of experience scaling specialty care platforms and building high-retention provider networks. He co-founded and built Extrakare LLC, a durable medical equipment company, giving him firsthand experience in the home medical equipment market that Accendra Health serves. Lloyd joins Accendra Health from Evergreen Nephrology, a national value-based kidney care platform, where he most recently served as Chief Development and Strategy Officer. He will work closely with Gardner-Smith to pair commercial execution with operating discipline, strengthening the Company's provider and payor relationships.

Safe Harbor

This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward looking” statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our financial performance, our 2026 financial results, our expectations regarding the performance of our business following the completion of the sale of the Products & Healthcare Services business, our cost saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the performance of our business, including our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, including the section captioned “Item 1A. Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at www.accendrahealth.com. Given these risks and uncertainties, the Company can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. The Company specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

About Accendra Health

Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology, and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio of essentials for diabetes, sleep health, wound care, respiratory care, urology, and ostomy, visit www.accendrahealth.com.

ACH-CORP

ACH-IR

Contacts

Investors

Will Parrish

Vice President, Strategy, Corporate Development, & Investor Relations

Investor.Relations@accendra.com

Media

Darla Turner

media@accendra.com

GRAPHIC

Filename: ach-20260916xex10d1g001.jpg · Sequence: 4

Binary file (151007 bytes)

Download ach-20260916xex10d1g001.jpg

GRAPHIC

Filename: ach-20260916xex10d1g002.jpg · Sequence: 5

Binary file (141543 bytes)

Download ach-20260916xex10d1g002.jpg

GRAPHIC

Filename: ach-20260916xex10d1g003.jpg · Sequence: 6

Binary file (128562 bytes)

Download ach-20260916xex10d1g003.jpg

GRAPHIC

Filename: ach-20260916xex10d1g004.jpg · Sequence: 7

Binary file (145329 bytes)

Download ach-20260916xex10d1g004.jpg

GRAPHIC

Filename: ach-20260916xex10d1g005.jpg · Sequence: 8

Binary file (161772 bytes)

Download ach-20260916xex10d1g005.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 14

v3.26.3

Document and Entity Information

Sep. 16, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Sep. 16, 2026

Entity Registrant Name

Accendra Health, Inc.

Entity Incorporation State Country Code

Entity File Number

001-09810

Entity Tax Identification Number

54-1701843

Entity Address Address Line 1

4435 Waterfront Drive, Suite 300

Entity Address City Or Town

Glen Allen

Entity Address Postal Zip Code

23060

Entity Address State Or Province

City Area Code

(804)

Local Phone Number

277-4304

Security 12b Title

Common Stock, $2 par value per share

Trading Symbol

ACH

Security Exchange Name

NYSE

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Entity Central Index Key

0000075252

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration